{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,11]],"date-time":"2026-07-11T19:08:27Z","timestamp":1783796907236,"version":"3.55.0"},"reference-count":37,"publisher":"Georg Thieme Verlag KG","issue":"07","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Horm Metab Res"],"published-print":{"date-parts":[[2021,7]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Angiogenesis is a multistep process implicated in the pathophysiology and\n                    progression of diabetic nephropathy (DN). Angiotensin-converting enzyme\n                    inhibitors (ACEI) and calcium channel blockers (CCB) have an important role in\n                    DN. We performed a randomized-controlled trial of lisinopril alone (an ACEI) or\n                    in combination with verapamil (a CCB) as a therapy for DN in type 2 diabetes\n                    mellitus (T2DM) patients with hypertension (HTN) and urinary albumin creatinine\n                    ratio (UACR) (30\u2013300\u2009mg\/g) also to evaluate their effect\n                    on UACR, the angiogenic proteins: Angiopoietin 2 (Ang-2) and Endostatin (EST).\n                    Forty T2DM patients with microalbuminuria, aged 45\u201365 years were\n                    included. Patients were randomly assigned into group 1 receiving oral lisinopril\n                    and group 2 receiving oral lisinopril and verapamil once daily. After 3 months\n                    follow-up fasting blood glucose (FPG), HbA1c, lipid profile, UACR, serum urea\n                    and creatinine levels were assessed. EST and Ang-2 were measured using ELISA\n                    technique. Baseline Ang-2 and EST levels were elevated in both groups compared\n                    with controls (p&lt;0.001). After follow-up, group 2 had significantly\n                    decreased FPG, HbA1c, UACR, EST and Ang-2 compared with their baseline levels\n                    (p&lt;0.001 for all comparisons) and with group 1 (p&lt;0.001). No\n                    adverse reactions were reported. Baseline EST and Ang-2 were positively\n                    correlated to UACR (r=0.753, p&lt;0.001) (r=0.685,\n                    p&lt;0.001). Lisinopril\/verapamil combination enhanced glycemic\n                    control and kidney function via diminishing EST and Ang-2. This combination can\n                    be considered as a safe and effective approach for early stage nephropathy\n                    therapy in T2DM.<\/jats:p>","DOI":"10.1055\/a-1517-6643","type":"journal-article","created":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:16:56Z","timestamp":1626740216000},"page":"470-477","source":"Crossref","is-referenced-by-count":9,"title":["Effect of Lisinopril and Verapamil on Angiopoietin 2 and Endostatin\n                    in Hypertensive Diabetic Patients with Nephropathy: A Randomized\n                    Trial"],"prefix":"10.1055","volume":"53","author":[{"given":"Al-Aliaa M.","family":"Sallam","sequence":"first","affiliation":[{"name":"Biochemistry Department, Faculty of Pharmacy, Ain Shams University,\n                    Cairo, Egypt"},{"name":"Biochemistry Department, Badr University in Cairo (BUC), Badr City,\n                    Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamed","family":"Salem","sequence":"additional","affiliation":[{"name":"Biochemistry Department, Faculty of Pharmacy, Ahram Canadian\n                    University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eman","family":"Abdel-Aleem","sequence":"additional","affiliation":[{"name":"Biochemistry Department, Faculty of Pharmacy, Ahram Canadian\n                    University, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8190-536X","authenticated-orcid":false,"given":"Hala O.","family":"El-Mesallamy","sequence":"additional","affiliation":[{"name":"Biochemistry Department, Faculty of Pharmacy, Ain Shams University,\n                    Cairo, Egypt"},{"name":"Biochemistry Department, Faculty of Pharmacy, Sinai University, Kantara\n                    Branch, Cairo, Egypt"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"194","published-online":{"date-parts":[[2021,7,19]]},"reference":[{"key":"ref1","first-page":"131","article-title":"Cellular and molecular aspects of diabetic nephropathy; The role of VEGF-A","volume":"35","author":"K Carranza","year":"2015","journal-title":"Nefrol [English Ed.] Socied Espa\u00f1 Nefrol"},{"key":"ref2","first-page":"444","article-title":"The pathogenesis of diabetic nephropathy","volume":"4","author":"S Dronavalli","year":"2008","journal-title":"Nat Rev"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/nrendo.2017.151","article-title":"Global aetiology and epidemiology of type 2 diabetes mellitus and its\n                    complications","volume":"14","author":"Y Zheng","year":"2018","journal-title":"Nat Rev Endocrin"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular\n                    filtration rate and albuminuria with all-cause and cardiovascular mortality in\n                    general population cohorts: A collaborative meta-analysis","volume":"375","author":"K Matsushita","year":"2010","journal-title":"Lancet"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.jdiacomp.2018.11.007","article-title":"Epidermal growth factor receptor and podocin predict nephropathy progression in\n                    type 2 diabetic patients through interaction with the autophagy influencer\n                    ULK-1","volume":"33","author":"AA A El-Shazly","year":"2019","journal-title":"J Diabetes Complications"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1007\/s10157-019-01744-3","article-title":"E-cadherin and periostin in early detection and progression of diabetic\n                    nephropathy: Epithelial-to-mesenchymal transition","volume":"23","author":"NM Q El-Dawla","year":"2019","journal-title":"Clin Exp Nephrol"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s12881-014-0103-8","article-title":"Meta-analysis of diabetic nephropathy associated genetic variants in\n                    inflammation and angiogenesis involved in different biochemical pathways","volume":"15","author":"N Nazir","year":"2014","journal-title":"BMC Med Genet"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1007\/s00268-016-3680-1","article-title":"Looking for the Word \u2018Angiogenesis\u2019 in the History of Health\n                    Sciences\u202f: From Ancient Times to the First Decades of the Twentieth Century","volume":"41","author":"G Natale","year":"2017","journal-title":"World J Surg"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.semnephrol.2007.01.007","article-title":"Angiogenesis in Diabetic Nephropathy","volume":"27","author":"R Zent","year":"2007","journal-title":"Semin Nephrol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1042\/CS20150403","article-title":"Vascular growth factors play critical roles in kidney glomeruli","author":"L Gnudi","year":"2015","journal-title":"Clin Sci"},{"key":"ref11","first-page":"895","article-title":"Association between interleukin-19 and angiopoietin-2 with vascular\n                    complications in type 2 diabetes","volume":"7","author":"L Li","year":"2016","journal-title":"Nat Pub Group"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1159\/000488826","article-title":"Angiopoietin-2, Renal deterioration, major adverse cardiovascular events and\n                    all- cause mortality in patients with diabetic nephropathy","volume":"807","author":"Y Tsai","year":"2018","journal-title":"Kidney Blood Press Res"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1161\/HYPERTENSIONAHA.113.02250","article-title":"Association Between Circulating Endostatin, Hypertension Duration, and\n                    Hypertensive Target-Organ Damage","author":"A C Carlsson","year":"2013","journal-title":"Hypertension"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.diabet.2016.03.006","article-title":"The association between endostatin and kidney disease and mortality in patients\n                    with type 2 diabetes","author":"A C Carlsson","year":"2016","journal-title":"Diabetes Metab"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/10641963.2014.933964","article-title":"The effects of calcium channel blockers on nephropathy and pigment\n                    epithelium-derived factor in the treatment of hypertensive patients with type 2\n                    diabetes mellitus","volume":"37","author":"T Sabuncu","year":"2015","journal-title":"Clin Exp Hypertens"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1038\/nrneph.2013.251","article-title":"The effect of RAAS blockade on the progression of diabetic nephropathy","volume":"10","author":"S Roscioni","year":"2014","journal-title":"Nat Rev Nephro"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1056\/NEJMoa1303154","article-title":"Combined angiotensin inhibition for the treatment of diabetic nephropathy","volume":"369","author":"L Fried","year":"2013","journal-title":"N Eng J Med"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1080\/20009666.2018.1500423","article-title":"Diabetic nephropathy: Newer therapeutic perspectives","volume":"8","author":"K C Keri","year":"2018","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"3691","DOI":"10.1111\/bph.15087","article-title":"Metabolic reprogramming by N-acetyl-seryl-aspartyl-lysyl-proline protects\n                    against diabetic kidney disease","volume":"177","author":"S P Srivastava","year":"2020","journal-title":"Br J Pharmacol"},{"key":"ref21","first-page":"S50","article-title":"Standards of medical care in diabetes-2015","volume":"38","author":"American Diabetes Association","year":"2015","journal-title":"Diabetes Care"},{"issue":"S 27","key":"ref22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1111\/pedi.12742","article-title":"ISPAD clinical practice consensus guidelines 2018: Microvascular and\n                    macrovascular complications in children and adolescents","volume":"19","author":"K C Donaghue","year":"2018","journal-title":"Pediatr Diabetes"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/jcp.22.2.158","article-title":"Determination of blood glucose using an oxidase-peroxidase system with a\n                    non-carcinogenic chromogen","volume":"22","author":"P Trinder","year":"1969","journal-title":"J Clin Pathol"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1046\/j.1523-1755.2002.00207.x","article-title":"Pyridoxamine inhibits early renal disease and dyslipidemia in the\n                    streptozotocin-diabetic rat","volume":"61","author":"T P Degenhardt","year":"2002","journal-title":"Kidney Int"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"10","DOI":"10.15586\/jrenhep.2017.17","article-title":"Concepts in Diabetic Nephropathy\u202f: From Pathophysiology to Treatment","volume":"1","author":"M Kinaan","year":"2017","journal-title":"J Renal Hepat Disord"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"1908","DOI":"10.3390\/jcm4111908","article-title":"Renin-angiotensin-aldosterone system blockade in diabetic nephropathy","volume":"4","author":"L Lozano-Maneiro","year":"2015","journal-title":"J Clin Med"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1186\/1477-7819-10-170","article-title":"Systematic review and meta-analysis of Endostar (rh-endostatin) combined with\n                    chemotherapy versus chemotherapy alone for treating advanced non-small cell lung\n                    cancer","volume":"10","author":"R Biaoxue","year":"2012","journal-title":"World J Surg Oncol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"55","DOI":"10.2147\/IBPC.S6232","article-title":"Current concepts in combination therapy for the treatment of hypertension:\n                Combined calcium channel blockers and RAAS inhibitors","author":"A F Rubio-guerra","year":"2009","journal-title":"Integr Blood Press Control"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"848","DOI":"10.2337\/db11-0955","article-title":"Preventing b -Cell Loss and Diabetes With Calcium Channel Blockers","volume":"61","author":"G Xu","year":"2012","journal-title":"Diabetes"},{"key":"ref30","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1210\/jc.2016-3778","article-title":"Verapamil use is associated with reduction of newly diagnosed diabetes\n                    mellitus","volume":"102","author":"T Yin","year":"2017","journal-title":"J Clin Endocr Metab"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.diabres.2016.01.021","article-title":"Calcium channel blocker use is associated with lower fasting serum glucose among\n                    adults with diabetes from the REGARDS study","volume":"115","author":"Y Khodneva","year":"2016","journal-title":"Diabet Res Clini Pract"},{"key":"ref32","first-page":"30: 682","article-title":"The effect of trandolapril and its fixed-dose combination with verapamil on\n                    circulating adhesion molecules levels in hypertensive patients with type 2\n                    diabetes","author":"A F Rubio-Guerra","year":"2008","journal-title":"Clin Exp Hypertens"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"87","DOI":"10.3109\/10641963.2012.690472","article-title":"Administration of Angiotensin Receptor II Blockade Improves Vascular Function,\n                    Urinary Albumin Excretion, and Left Ventricular Hypertrophy in Low-Risk\n                    Essential Hypertensive Patients Receiving Antihypertensive Treatment with\n                    Calcium Channel Blockers","volume":"35","author":"Y Watanabe","year":"2013","journal-title":"Clin Exp Hypertens"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1111\/jch.12771","article-title":"Angiotensin System Blockade Combined With Calcium Channel Blockers Is Superior\n                    to Other Combinations in Cardiovascular Protection With Similar Blood Pressure\n                    Reduction: A Meta-Analysis in 20, 451 Hypertensive Patients","volume":"18","author":"C Chi","year":"2016","journal-title":"J Clin Hypertens"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1007\/s13410-018-0679-1","article-title":"Serum Angiopoietin-2 levels as a marker in type 2 diabetes mellitus\n                complications","author":"K Siddiqui","year":"2019","journal-title":"Int J Diabetes Dev Ctries"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1172\/JCI11771","article-title":"Development and prevention of advanced diabetic nephropathy in\n                    RAGE-overexpressing mice","volume":"108","author":"J Invest","year":"2001","journal-title":"J Clin Investigat"},{"key":"ref38","first-page":"84","article-title":"T-Type Ca Channel Blockade as a Determinant of Kidney Protection","author":"K Rosenthal","year":"2010","journal-title":"Keio J Med"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"177","DOI":"10.3109\/10641963.2014.933964","article-title":"The effects of calcium channel blockers on nephropathy and pigment\n                    epithelium-derived factor in the treatment of hypertensive patients with type 2\n                    diabetes mellitus","volume":"37","author":"S Tabur","year":"2015","journal-title":"Clin Exp Hypertens"}],"container-title":["Hormone and Metabolic Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1517-6643.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,20]],"date-time":"2021-07-20T00:21:13Z","timestamp":1626740473000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1517-6643"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,7]]},"references-count":37,"journal-issue":{"issue":"07","published-online":{"date-parts":[[2021,7,19]]},"published-print":{"date-parts":[[2021,7]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1517-6643","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0018-5043","1439-4286"],"issn-type":[{"value":"0018-5043","type":"print"},{"value":"1439-4286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7]]}}}